
News|Videos|December 12, 2025
IMvigor011: A Phase 3 Trial of Circulating Tumour (ct)DNA-Guided Adjuvant Atezolizumab vs Placebo in Muscle-Invasive Bladder Cancer
Author(s)Thomas Powles MBBS, MRCP, MD
Thomas Powles, MBBS, MRCP, MD discusses IMvigor011: a Phase 3 trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer.
Advertisement
Thomas Powles, MBBS, MRCP, MD discusses how, his study reports that in the phase 3 IMvigor011 trial, ctDNA-positive patients with muscle-invasive bladder cancer who received adjuvant atezolizumab had statistically significant improvements in both disease-free survival and overall survival compared with placebo. The results support using serial ctDNA monitoring to identify patients who benefit from immunotherapy while safely sparing persistently ctDNA-negative patients from unnecessary treatment.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5



































